Citigroup lowered shares of Atara Biotherapeutics (NASDAQ:ATRA) from a neutral rating to a sell rating in a research note issued to investors on Thursday, February 15th, MarketBeat reports.
A number of other equities research analysts have also recently commented on ATRA. Canaccord Genuity reaffirmed a buy rating on shares of Atara Biotherapeutics in a research note on Thursday, November 9th. ValuEngine raised Atara Biotherapeutics from a sell rating to a hold rating in a research note on Friday, December 29th. BidaskClub raised Atara Biotherapeutics from a hold rating to a buy rating in a research note on Thursday, January 11th. Cowen started coverage on Atara Biotherapeutics in a research note on Friday, January 26th. They set an outperform rating for the company. Finally, Zacks Investment Research cut Atara Biotherapeutics from a hold rating to a sell rating in a research note on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $33.80.
Shares of Atara Biotherapeutics (NASDAQ ATRA) opened at $46.05 on Thursday. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $49.90. The company has a market capitalization of $1,990.00, a price-to-earnings ratio of -11.54 and a beta of 2.59.
Large investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in Atara Biotherapeutics in the third quarter valued at about $142,000. Voya Investment Management LLC grew its stake in Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,651 shares during the period. Russell Investments Group Ltd. acquired a new position in Atara Biotherapeutics in the third quarter valued at about $170,000. MetLife Investment Advisors LLC acquired a new position in Atara Biotherapeutics in the fourth quarter valued at about $217,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 1,369 shares in the last quarter. 76.88% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2018/03/13/citigroup-downgrades-atara-biotherapeutics-atra-to-sell.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.